



68811-A.ST25.txt  
SEQUENCE LISTING

<110> Cohen-Vered, et al., Sharon

<120> PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

<130> 2609/68811-A

<140> 10/758,397

<141> 2004-01-14

<160> 18

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 1

Thr Gly Tyr Tyr Met Gln Trp Val Lys Gln Ser Pro Glu Lys Ser Leu  
1 5 10 15

Glu Trp Ile Gly  
20

<210> 2

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 2

Glu Ile Asn Pro Ser Thr Gly Gly Thr Thr Tyr Asn Gln Lys Phe Lys  
1 5 10 15

Ala Lys Ala Thr  
20

<210> 3

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 3

Tyr Tyr Cys Ala Arg Phe Leu Trp Glu Pro Tyr Ala Met Asp Tyr Trp  
1 5 10 15

Gly Gln Gly Ser  
20

<210> 4

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 4

Gly Tyr Asn Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu  
1 5 10 15

Trp Ile Gly

<210> 5

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 5

Tyr Tyr Cys Ala Arg Ser Gly Arg Tyr Gly Asn Tyr Trp Gly Gln Thr  
1 5 10 15

Leu

<210> 6

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 6

Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu  
1 5 10 15

Trp Ile Gly

<210> 7

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 7

Tyr Tyr Cys Ala Arg Gly Leu Leu Arg Gly Gly Trp Asn Asp Val Asp  
1 5 10 15

Tyr Tyr Gly Met Asp Val  
20

<210> 8

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 8

Phe Ser Gly Tyr Tyr Trp Ser  
1 5

<210> 9

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<400> 9

Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Lys Thr Ser Leu Lys Ser  
1 5 10 15

<210> 10

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody  
Page 4

<400> 10

Gly Leu Leu Arg Gly Gly Trp Asn Asp Val Asp Tyr Tyr Tyr Gly Met  
 1 5 10 15

Asp Val

<210> 11

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> X= Met, Ala or Val

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> X= Gln, Asp, Glu or Arg

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> X= Trp or Ala

<220>

<221> MISC\_FEATURE

<222> (8)..(8)

<223> X= Val or Ser

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (9)..(9)

&lt;223&gt; X= Lys, Glu or Ala

&lt;400&gt; 11

Thr Gly Tyr Tyr Xaa Xaa Xaa Xaa Xaa Gln Ser Pro Glu Lys Ser Leu  
 1 5 10 15

Glu Trp Ile Gly  
 20

&lt;210&gt; 12

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide based on CDR of mouse autoantibody

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (9)..(9)

&lt;223&gt; X= Thr, Val or Ala

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (10)..(10)

&lt;223&gt; X= Thr, Val or Ala

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (11)..(11)

&lt;223&gt; X= Tyr or Phe

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (12)..(12)

&lt;223&gt; X= Asn or Asp

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (13)..(13)

&lt;223&gt; X =Gln or Glu

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (14)..(14)

&lt;223&gt; X= Lys or Glu

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (15)..(15)

&lt;223&gt; X= Phe or Tyr

&lt;400&gt; 12

Glu Ile Asn Pro Ser Thr Gly Gly Xaa Xaa Xaa Xaa Xaa Xaa Lys  
 1 5 10 15

Ala Lys Ala Thr  
 20

&lt;210&gt; 13

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> X= Phe, Thr or Gly

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> X= Leu, Ala or Ser

<220>

<221> MISC\_FEATURE

<222> (8)..(8)

<223> X= Trp or Ala

<220>

<221> MISC\_FEATURE

<222> (9)..(9)

<223> X= Glu or Lys

<220>

<221> MISC\_FEATURE

<222> (13)..(13)

<223> X= Met or Ala

<220>

<221> MISC\_FEATURE

<222> (14)..(14)

<223> X= Asp, Lys or Ser



<400> 13

Tyr Tyr Cys Ala Arg Xaa Xaa Xaa Xaa Pro Tyr Ala Xaa Xaa Tyr Trp  
1 5 10 15

Gly Gln Gly Ser  
20

<210> 14

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> X= Met or Ala

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> X= Asn, Asp or Arg

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> X= Trp or Ala

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> X= Val or Ser

<220> -----

<221> MISC\_FEATURE

<222> (8)..(8)

<223> X= Lys or Glu

<220>

<221> MISC\_FEATURE

<222> (9)..(9)

<223> X= Gln or Ala

<220>

<221> MISC\_FEATURE

<222> (13)..(13)

<223> X= Lys or Glu

<220>

<221> MISC\_FEATURE

<222> (14)..(14)

<223> X= Ser or Ala

<400> 14

Gly Tyr Asn Xaa Xaa Xaa Xaa Xaa Xaa Ser His Gly Xaa Xaa Leu Glu  
1 5 10 15

Trp Ile Gly

<210> 15

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide based on CDR of mouse autoantibody

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> X= Ser or Phe

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> X= Gly or Ala

<220>

<221> MISC\_FEATURE

<222> (8)..(8)

<223> X= Arg, Ala or Glu

<220>

<221> MISC\_FEATURE

<222> (11)..(11)

<223> X= Asn or Asp

<220>

<221> MISC\_FEATURE

<222> (12)..(12)

<223> X= Tyr or Phe

<220>

<221> MISC\_FEATURE

<222> (13)..(13)

<223> X= Trp, His or Ala

&lt;400&gt; 15

Tyr Tyr Cys Ala Arg Xaa Xaa Xaa Tyr Gly Xaa Xaa Xaa Gly Gln Thr  
 1 5 10 15

Leu

&lt;210&gt; 16

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide basedon CDR of mouse autoantibody

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; X= Gly or Thr Gly

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (8)..(8)

&lt;223&gt; X= Arg or Lys

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (10)..(10)

&lt;223&gt; X= Pro or Ser

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (12)..(12)

&lt;223&gt; X= Gly or Glu

<220>

<221> MISC\_FEATURE

<222> (13)..(13)

<223> X= Lys or Asp

<220>

<221> MISC\_FEATURE

<222> (15)..(15)

<223> X= Glu, Leu or Ser

<400> 16

Xaa Tyr Tyr Trp Ser Trp Ile xaa Gln xaa Pro xaa xaa Gly xaa Glu  
 1 5 10 15

Trp Ile Gly

<210> 17

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide basedon CDR of mouse autoantibody

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> X= Gly or Phe

<220>

<221> MISC\_FEATURE

<222> (9)..(9)

<223> X= Arg or Ala

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (10)..(10)

&lt;223&gt; X= Gly or Ala

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (11)..(11)

&lt;223&gt; X= Gly or Ala

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (12)..(12)

&lt;223&gt; X= Trp or Ala

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (13)..(13)

&lt;223&gt; X= Asn or Ala

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (18)..(18)

&lt;223&gt; X= Tyr or Trp

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (20)..(20)

&lt;223&gt; X= Met or Gln

&lt;400&gt; 17

Tyr Tyr Cys Ala Arg Xaa Leu Leu Xaa Xaa Xaa Xaa Xaa Asp Val Asp  
 1 5 10 15

Tyr Xaa Gly Xaa Asp Val  
 20

<210> 18

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide of 19 amino acids based on the complementarity-  
 determining region 1 (CDR1) of human anti-dsDNA mAb denoted 16/6  
 Id

<400> 18

Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu  
 1 5 10 15

Trp Ile Gly